Interim report July 1- September 30, 2024
24 October, 2024
Summary of the first quarter (2024-07-01 – 2024-09-30)
• Net sales amounted to MSEK 0,0 (0,0)
• Operating profit/loss amounted to MSEK -1,3 (-1,1)
• Earnings per share* SEK -0.06 (-0.05)
• Cash and cash equivalents at the end of the period amounted to MSEK 17,9 (19,0)
* Before and after dilution. Earnings per share: Profit for the period divided by the average number of shares 18,485,857. For the comparison period, the average number of shares was 18,485,857. Amounts in brackets refer to the corresponding period last year.
Comments from the CEO
The latest results from the Company’s ongoing myeloma study, which was announced in August, showed that three out of four patients had stable disease after completing treatment. Stable disease means a slowing down of the course of the disease where the cancer does not progress. The patients who can be included in the study (inclusion criteria), must have relapsed/treatment-resistant disease and received 1-5 prior lines of therapy. The results are very important and promising, indicating that OsteoDex can slow relapsed/treatment-resistant disease. In addition, a clear decreasing effect on biomarkers related to bone cells, especially osteoclasts activity (bone resorption) is noted. Significantly, no OsteoDex related serious adverse events (SAEs) have been noted. The study is now progressing towards the two higher dose ranges of 6mg/kg and 9mg/kg. Patients who achieve stable disease after completion of treatment will be followed up until new progression, according to the approved amendment, which provides information on how long the treatment effect lasts.
General information about the study: Conducted at Uddevalla Hospital, Dr Dorota Knut, and Dr Katarina Uttervall dept. Haematology/HERM, Karolinska University Hospital, Huddinge, Katarina Uttervall is principal investigator (PI). Biomarkers are analysed at the Central Laboratory, Karolinska University Hospital, NKS, Solna. The primary objective is to confirm safety and tolerability and as a secondary objective to determine treatment response. Documentation of quality of life will also be done (QoL scores).
Anders R Holmberg